Targeted Therapy Extends Progression-Free Survival in HER2-Positive Metastatic Breast Cancer
New clinical trial data demonstrate that adding a targeted therapy to the maintenance phase of treatment can considerably prolong the time before disease progression in patients with metastatic breast cancer, particularly those with HER2-positive tumors. This strategy offers the potential to delay the need for resuming chemotherapy, improving quality of life and extending periods of disease stability.
Key Findings from a Landmark Clinical trial
A recent, advanced clinical trial involving 654 patients diagnosed with HER2-positive metastatic breast cancer revealed a substantial benefit from incorporating a tyrosine kinase inhibitor into maintenance therapy. All participants had previously completed initial treatment with chemotherapy combined with trastuzumab (Herceptin) and pertuzumab (Perjeta) – monoclonal antibodies from Roche – without evidence of disease progression. Following this initial phase, patients were randomly assigned to receive either the tyrosine kinase inhibitor or a placebo, in addition to continued trastuzumab and pertuzumab maintenance therapy.
After a median follow-up of 23 months, patients receiving the tyrosine kinase inhibitor achieved progression-free survival exceeding two years – a notable betterment of 8.6 months compared to the placebo group. Progression-free survival refers to the length of time during which the disease remains stable and does not worsen. These findings were presented at the San Antonio Breast Cancer Symposium,a leading international breast cancer research meeting,and subsequently published in the Journal of Clinical Oncology (JCO).
Understanding the Mechanism: Targeting HER2
Tyrosine kinase inhibitors are a class of drugs designed to block the HER2 protein found on cancer cells. By inhibiting this protein, these drugs effectively slow or halt tumor growth. The study highlights the importance of continued, intensified HER2 targeting even after initial treatment success.
“Extending the maintenance phase allows maintaining control over the disease and extends the period in which patients can remain without chemotherapy,” explained Dr. Erika Hamilton, study coordinator from the Sarah Cannon Research Institute in Nashville. Currently, many patients experience disease progression within two years of initiating treatment and require a return to chemotherapy. This new approach aims to address this challenge.
hormonal Receptor Status Influences Treatment Response
Subgroup analysis revealed variations in treatment response based on the status of hormonal receptors. Patients with HR-negative tumors